Cti Biopharma Corp Stock
Your prediction
Pros and Cons of Cti Biopharma Corp in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cti Biopharma Corp vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cti Biopharma Corp | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -0.810% | -1.575% | -6.015% | -19.355% | -24.699% | -54.545% | -83.333% |
| Celldex Therapeutics | -1.530% | 1.587% | -12.727% | -11.111% | -12.727% | -50.920% | -9.177% |
| Achieve Life Sciences Inc. | -0.570% | 2.332% | -25.793% | 9.006% | -5.135% | -29.716% | -71.230% |
Comments
CTI BioPharma Corp. (NASDAQ: CTIC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Show more
Ratings data for CTIC provided by MarketBeat
CTI BioPharma Corp. (NASDAQ: CTIC) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $9.00 price target on the stock.
Show more
Ratings data for CTIC provided by MarketBeat
